About the Event
bit.bio, a synthetic biology company that was spun out of Cambridge University in 2016, has achieved a breakthrough in cell therapy. Their Opti-ox precision platform has the ability to create any human cell type and to manufacture it at scale with precision and consistency.
Register now to join this webinar with:
- Mark Kotter, MD, PhD, Founder and CEO, bit.bio
Mark is a stem cell biologist and neurosurgeon at the University of Cambridge, the founder of bit.bio and co-founder of the cultured meat start-up Meatable.
- Alan S. Roemer, MBA, MPH, Board Member, bit.bio
Alan is an entrepreneurial life sciences executive and board member who has launched three multi-billion dollar biotechnology companies, raised over $1.75 billion in private and public capital, consummated five IPOs, and executed numerous life sciences technology transactions.
- Marie-Claire Cordonier Segger, PhD (Santa), DPhil (Oxon), MEM (Yale), LLB&BCL (McGill), BA Hons (Carl/UVic), FRSC, FRSA, WIJA, Chair of Ethics and Sustainability Board and Advisor to the Board, bit.bio
Marie-Claire is Visiting Chair of Sustainable Development Law and Policy at the University of Cambridge, and also serves as Senior Director of the global Centre for International Sustainable Development Law (CISDL). Having assisted in drafting the Paris Agreement, she has published over 24 books and 160 papers and edited five law journals. She has advised the United Nations, several countries, and companies to advance the UN Sustainable Development Goals.